AbCellera Biologics (ABCL) Leases (2021 - 2025)
AbCellera Biologics (ABCL) has disclosed Leases for 5 consecutive years, with $137.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases rose 101.87% year-over-year to $137.9 million, compared with a TTM value of $137.9 million through Sep 2025, up 101.87%, and an annual FY2024 reading of $66.6 million, down 8.88% over the prior year.
- Leases was $137.9 million for Q3 2025 at AbCellera Biologics, up from $136.9 million in the prior quarter.
- Across five years, Leases topped out at $137.9 million in Q3 2025 and bottomed at $6.6 million in Q1 2022.
- Average Leases over 5 years is $61.9 million, with a median of $68.5 million recorded in 2024.
- Peak annual rise in Leases hit 632.47% in 2023, while the deepest fall reached 9.52% in 2023.
- Year by year, Leases stood at $19.8 million in 2021, then skyrocketed by 308.27% to $80.8 million in 2022, then decreased by 9.52% to $73.1 million in 2023, then decreased by 8.88% to $66.6 million in 2024, then surged by 106.93% to $137.9 million in 2025.
- Business Quant data shows Leases for ABCL at $137.9 million in Q3 2025, $136.9 million in Q2 2025, and $68.7 million in Q1 2025.